AMOTL (angiomotin like) Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verteporfin | 129497-78-5 | sc-475698 sc-475698A | 10 mg 100 mg | $347.00 $2710.00 | 5 | |
Verteporfin, a photosensitizer, indirectly inhibits Angiomotin-L2 by disrupting the Hippo signaling pathway. It activates YAP/TAZ degradation, impacting the expression and function of Angiomotin-L2 within the Hippo pathway and subsequently leading to its inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, indirectly inhibits AMOTL (angiomotin like) by targeting Src family kinases. By disrupting the activation of Src, Dasatinib modulates downstream signaling pathways, influencing AMOTL (angiomotin like) expression and function within cellular processes associated with Src-mediated pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632, a selective Rho-associated protein kinase (ROCK) inhibitor, indirectly inhibits AMOTL (angiomotin like) through the regulation of actin cytoskeleton dynamics. By targeting ROCK, Y-27632 influences cellular processes that impact Angiomotin-L2, leading to its modulation within the context of actin cytoskeleton-associated pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly inhibits AMOTL (angiomotin like) by disrupting the mTOR signaling pathway. It modulates downstream events that influence AMOTL (angiomotin like) expression and function within cellular processes associated with mTOR-mediated pathways, leading to its inhibition. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, indirectly inhibits AMOTL (angiomotin like) by targeting various kinases involved in angiogenesis and cellular signaling. Through the modulation of these kinases, Sorafenib influences AMOTL (angiomotin like) expression and function within cellular processes associated with angiogenesis and related pathways. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $306.00 $465.00 $1102.00 | 3 | |
PF-562271, a focal adhesion kinase (FAK) inhibitor, indirectly inhibits AMOTL (angiomotin like) by disrupting FAK-mediated signaling pathways. This inhibitor influences downstream events that impact AMOTL (angiomotin like) expression and function within cellular processes associated with FAK-related pathways, leading to its modulation. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib, a tyrosine kinase inhibitor, indirectly inhibits AMOTL (angiomotin like) by targeting specific tyrosine kinases. By disrupting these kinases, Imatinib modulates downstream signaling pathways, influencing AMOTL (angiomotin like) expression and function within cellular processes associated with these tyrosine kinase-mediated pathways. | ||||||